following a full submission assessed under the orphan medicine process:
ocrelizumab (Ocrevus®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
In a randomised, double-blind, phase III study, the risk of disability progression was significantly reduced in patients who received ocrelizumab compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- ocrelizumab (Ocrevus)
- SMC ID:
- SMC2223
- Indication:
For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published:
- 13 January 2020